The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market.

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory follicular lymphoma (FL).

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

MAXONA Pharmaceuticals has submitted an IND application seeking approval from the US FDA for its lead compound, MAX-001, to treat acute pain.

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Bayer disclosed that its Q2 earnings were inflated by transfer fees at its German football club Bayer Leverkusen.

The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.

Astria has made an exclusive licensing agreement with Kaken for the development and commercialisation rights of navenibart in Japan.

Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...